Magnetic resonance spectroscopy for monitoring neuronal integrity in amyotrophic lateral sclerosis

Advances in Experimental Medicine and Biology

Volumn 576, Issue , 2006, Pages 275-282

  Kalra, Sanjay ^a   Arnold, Douglas L ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934442173     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-30172-0_19     Document Type: Conference Paper

References (49)

1. Martin,J.E. and Swash,M. The pathology of motor neuron disease. In: Motor Neuron Disease. Biology and Management., edited by Leigh,P.N. and Swash,M. London: Springer-Verlag, 1995, p. 93-118.
2. . B.R. Brooks, R.G. Miller, M. Swash and T.L. Munsat, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord 1(5), 293-299 (2000).
3. C. Lomen-Hoerth, J. Murphy, S. Langmore, et al, Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 60(7), 1094-1097 (2003).
4. Amyotrophic Lateral Sclerosis, edited by H. Mitsumoto, D. Chad, and E.P. Pioro: Philadelphia:F.A. Davis Company, 1998.
5. L. Lacomblez, G. Bensimon, P.N. Leigh, P. Guillet and V. Meininger, Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lancet 347(9013), 1425-1431 (1996).
6. B. Brownell, D.R. Oppenheimer and J.T. Hughes, The central nervous system in motor neurone disease, J Neurol Neurosurg Psychiatry 33(3), 338-357 (1970).
7. T. Lawyer and M.G. Netsky, Amyotrophic lateral sclerosis: a clinicoanatomic study of fifty-three cases, Arch Neurol Psychiatry 69, 171-192 (1953).
8. D.K. Leung DK, A.P. Hays, K. Geysu, M.L. DelBene and L.P. Rowland, Diagnosis of ALS: clinicopathologic analysis of 76 autopsies, Neurology 52(Suppl 2), A164 (1999).
9. P.G. Ince, J. Evans, M. Knopp, et al, Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS, Neurology 60(8), 1252-1258 (2003).
10. S. Kalra and D. Arnold, Neuroimaging in amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord 4(4), 243-248 (2003).
11. M.L. Simmons, C.G. Frondoza and J.T. Coyle, Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies, Neuroscience 45(1), 37-45 (1991).
12. J.R. Moffett, M.A. Namboodiri, C.B. Cangro and J.H. Neale, Immunohistochemical localization of N-acetylaspartate in rat brain, Neuroreport 2(3), 131-134 (1991).
13. J. Battistuta, C. Bjartmar and B.D. Trapp, Postmortem degradation of N-acetyl aspartate and N-acetyl aspartylglutamate: an HPLC analysis of different rat CNS regions, Neurochem Res 26(6), 695-702 (2001).
14. O. Gredal, S. Rosenbaum, S. Topp, et al, Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy, Neurology 48(4), 878-881 (1997).
15. B.C. Bowen, P.M. Pattany, W.G. Bradley, et al, MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis, AJNR Am J Neuroradiol 21(4), 647-658 (2000).
16. C. Pohl, W. Block, J. Karitzky, et al, Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis, Arch Neurol 58(5), 729-735 (2001).
17. P. Sarchielli, G.P. Pelliccioli, R. Tarducci, et al, Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis, Neuroradiology 43(3), 189-197 (2001).
18. E.P. Pioro, J.P. Antel, N.R. Cashman and D.L. Arnold, Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo, Neurology 44(10), 1933-1938 (1994).
19. A.P. Jones, W.J. Gunawardena, C.M. Coutinho, et al, Preliminary results of proton magnetic resonance spectroscopy in motor neurone disease (amyotrophic lateral sclerosis), J Neurol Sci 129 Suppl 85-89 (1995).
20. M. Giroud, P. Walker, D. Bernard, et al, Reduced brain N-acetyl-aspartate in frontal lobes suggests neuronal loss in patients with amyotrophic lateral sclerosis, Neurological Research 18(3), 241-243 (1996).
21. W.D. Rooney, R.G. Miller, D. Gelinas, et al, Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS, Neurology 50(6), 1800-1805 (1998).
22. W. Block, J. Karitzky, F. Traber, et al, Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements, Arch Neurol 55(7), 931-936 (1998).
23. M.J. Strong, G.M. Grace, J.B. Orange, et al, A prospective study of cognitive impairment in ALS, Neurology 53(8), 1665-1670 (1999).
24. S. Vielhaber, J. Kaufmann, M. Kanowski, et al, Effect of creatine supplementation on metabolite levels in ALS motor cortices, Exp Neurol 172(2), 377-382 (2001).
25. N. Schuff, W.D. Rooney, R. Miller, et al, Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis, Magn Reson Med 45(3), 513-516 (2001).
26. K. Abe, M. Takanashi, Y. Watanabe, et al, Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis, Neuroradiology 43(7), 537-541 (2001).
27. W. Kenn, G. Ochs, T.A. Pabst and D. Hahn, 1H spectroscopy in patients with amyotrophic lateral sclerosis, J Neuroimaging 11(3), 293-297 (2001).
28. C.C. Hanstock, V.A. Cwik and W.R. Martin, Reduction in metabolite transverse relation times in amyotrophic lateral sclerosis, J Neurol Sci 198 37-41 (2002).
29. J. Suhy, R.G. Miller, R. Rule, et al, Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI, Neurology 58(5), 773-779 (2002).
30. V.A. Cwik, C.C. Hanstock, P.S. Allen and W.R. Martin, Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy, Neurology 50(1), 72-77 (1998).
31. S. Kalra, A. Genge and D. Arnold, A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results, Amyotroph Lateral Scler Other Motor Neuron Disord 4(1), 22-26 (2003).
32. S. Kalra, N.R. Cashman, Z. Caramanos, A. Genge and D.L. Arnold, Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy, Am J Neuroradiol 24(3), 476-480 (2003).
33. E.P. Pioro, A.W. Majors, H. Mitsumoto, D.R. Nelson and T.C. Ng, 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla, Neurology 53(1), 71-79 (1999).
34. Parent,A. Carpenter's Human Neuroanatomy, Baltimore: Williams and Wilkins, 1996. Ed.9 pp. 864-936.
35. C. Pohl, W. Block, F. Traber, et al, Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients, J Neurol Sci 190(1-2), 21-27 (2001).
36. C.M. Ellis, A. Simmons, C. Andrews, et al, A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings, Neurology 51(4), 1104-1109 (1998).
37. V.A. Cwik, C.C. Hanstock, C. Boyd, et al, Regional neuronal dysfunction in amyotrophic lateral sclerosis (ALS): in vivo measurement with proton magnetic resonance spectroscopy (MRS), Neurology 48(Suppl 2), A216 (1997).
38. S. Kalra, N.R. Cashman, A. Genge and D.L. Arnold, Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy, Neuroreport 9(8), 1757-1761 (1998).
39. S. Kalra, A. Genge, N.R. Cashman, and D.L. Arnold, 1H-MRSI demonstrates a regional decline in corticoneuronal integrity in amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord 2(Suppl 2), 118-119 (2001).
40. Matthews P M, Cianfaglia L, McLaurin J, et al. Proceedings of the Society of Magnetic Resonance and the European Society for Magnetic Resonance in Medicine and Biology 1 147 (1995) (Abstract)
41. B.G. Jenkins, P. Klivenyi, E. Kustermann, et al, Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice, J Neurochem 74(5), 2108-2119 (2000).
42. C. Gasparovic, N. Arfai, N. Smid and D.M. Feeney, Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury, J Neurotrauma 18(3), 241-246 (2001).
43. C. Demougeot, P. Garnier, C. Mossiat, et al, N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury, J Neurochem 77(2), 408-415 (2001).
44. N. De Stefano, P.M. Matthews and D.L. Arnold, Reversible decreases in N-acetylaspartate after acute brain injury, Magn Reson Med 34(5), 721-727 (1995).
45. S. Narayanan, N. De Stefano, G.S. Francis, et al, Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b, J Neurol 248(11), 979-986 (2001).
46. M. Uno, S. Ueda, H. Hondo, K. Matsumoto and M. Harada, Effectiveness of revascularization surgery evaluated by proton magnetic resonance spectroscopy and single photon emission computed tomography, Neurol. Med. Chir. (Tokyo) 36(8), 560-566 (1996).
47. F. Cendes, F. Andermann, F. Dubeau, P.M. Matthews and D.L. Arnold, Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging, Neurology 49(6), 1525-1533 (1997).
48. J. Vion-Dury, F. Nicoli, A.M. Salvan, et al, Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy, Lancet 345(8941), 60-61 (1995).
49. O.A. Andreassen, B.G. Jenkins, A. Dedeoglu, et al, Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation, J Neurochem 77(2), 383-390 (2001).